COPHy 2023: Presence of macular neovascularisation on OCTA is predictive of subsequent exudation
March 24th 2023Angela Carneiro, MD, PhD, discusses her position on a discussion titled Presence of Macular Neovascularization on OCTA is Predictive of Subsequent Exudation with David Hutton, Executive Editor, Ophthalmology Times®.
Angiogenesis: High-dose aflibercept demonstrates safety, efficacy in treatment of DME
February 28th 2023David S. Boyer, MD, presented data from the PHOTON study examining the safety and efficacy of high-dose aflibercept for treatment of diabetic macular edema at the 2023 Angiogenesis, Exudation, and Degeneration conference.
Phase 3 study of CPN-302: Positive topline results for post-cataract surgery drug candidate
August 13th 2022The companies note that data from Study CPN-302 confirm the results in the first Phase 3 study, CPN-301, and they demonstrate the clear benefits of treating patients after cataract surgery with APP13007.
Enrolment begins in Phase 2 study for therapeutic for persistent corneal epithelial defects
July 10th 2022Kiora Pharmaceuticals announced it has enrolled the first patient as a part of a Phase 2 study evaluating KIO-201 topical eye drops in patients with PCED, a rare ocular surface condition characterized by non-healing wounds on the eye surface.
Intraventricular haemorrhage in first year may lead to long-term sight problems
July 9th 2022Researchers at the University of Bristol, as part of a 10-year follow-up study, found that severe “brain bleeds” experienced by some babies in the first year following their birth lead to long-term sight problems.
Self-plugging microneedles may improve drug delivery in the eye
June 27th 2022In a recent study, investigators found preclinical evidence that this innovative, biodegradable microneedle, dip-coated with a therapeutic drug for release upon insertion into the eyeball, can also be equipped with a special hydrogel that simultaneously seals off the insertion hole.